Dr. Bruce Bugbee president and CEO of Apogee Instruments, Inc. A professor and researcher at Utah State University. R&D and production of Apogee has grown into a world-class manufacturer of environmental sensors, a state-of-the-art headquarters and manufacturing facility. The keys to Apogee's success has been Dr. Bugbee passion for creating top-quality, cost-effective instrumentation for scientists that meet his own rigorous performance standards in the field and the lab.
Video: Maximizing Cannabis Yields for Home Growers with Dr Bruce Bugbee
The new Israeli cannabis company "Univo" reports that it has basically agreed to import about half a ton of medical cannabis from the Canadian cannabis company "Canopy".
470 kg of cannabis will be imported into Israel from the world's largest cannabis company, says the new Israeli cannabis company UNV Medicine LTD. Univo which will be the exclusive importer of cannabis in Israel from Canopy.
Cannabis's products that will be shipped to Israel were not designed to be labelled Canada's famous brand, including "Tweed" and "Spectrum", but would be branded as "Unvio" products.
The announcement of the import from "Canopy" comes after the import of 250 kg made by Canndoc Ltd. "Canndoc" from the Canadian cannabis company "Tilray", and 400 kg of cannabis imported by the "Bazelet" members of the Portuguese farm company "Emek". In addition, the company "Together" announced it will import 250 kg of cannabis from its cannabis farm in Uganda.
After Tweed Canopy's imports are realized in Israel, cannabis from overseas of a total weight of over 1.3 tons, following the Ministry of Health approval for companies to import in view of the status of local cannabis deficiency.
This phenomenon of importing cannabis from abroad is expected to seriously harm small Israeli farmers who hoped to establish Israeli cannabis reviews for marketing the produce to factories. Collaboration agreements with the largest Canadian companies in the peripheral world, a large part of the activity share in this area.
According to Univo's announcement to the stock exchange: "Along with exclusive engagement in Israel, Univo will first import 470 kilograms of dry medical cannabis grown by canopy, produce its products with the cannabis raw materials that carry Univo's logo and brand and find the national cannabis products. Exclusively, as final packaging in pharmacies for the Israeli market. ”
It is also reported that "Univo's imported product is the GACP librarian, from which Unibo will produce GMP paper products and subject to the certification and instructions of the Medical Cannabis Unit of the Ministry of Health. The second home of the European Cannabis Medical Memorandum and Memorandum in Europe, the European market For the required permits. "
Golan Bitton, Univo's CEO, said: "The agreement with Canopy is a move. In addition, the agreement is proof that there is a right in establishing a technology enterprise with a larger capacity that the technology will produce products of international quality and standards. The agreement will also allow us to define our market share in Israel, regardless of our farms and professional supplies and continue to sell to expand our range of medical cannabis products.
Source: Cannabis Magazine
First discovered in Israel in the 1960s by Professor Raphael Mechoulam and his team, cannabinoids are naturally occurring chemical compounds derived from the cannabis plant. These compounds are responsible for the many medicinal effects of cannabis, with each compound offering distinctive properties and benefits. To date, scientists have discovered over 113 cannabinoids, and more are likely to be found.
Your body responds to every cannabinoid compound differently thanks to a remarkable built-in mechanism: the endocannabinoid system. This complex system is made up of receptors scattered throughout the body, which regulate health and homeostasis. The receptors have been identified in nearly every major organ system, from the brain and spinal cord to the gastrointestinal tract. CB1 receptors are associated most closely with the brain and nervous system, while CB2 receptors are linked to the immune system. These receptors, along with enzymes that aid in cleanup after many endocannabinoid system processes, help our bodies maintain a stable internal environment.
When activated by exposure to cannabinoids, the receptors of the endocannabinoid system become reactive. This means they’re able to affect key body processes including mood, memory, appetite, and pain. The specific effects of cannabis-derived products depend on the particular compound used and the location of the receptors that bind with that compound; we’ll look more closely at the receptor-cannabinoid interactions of various CBD compounds in the sections below.
The most familiar of the cannabinoids is CBD, an abbreviation that’s short for cannabidiol. Unlike THC, the other well-known compound derived from cannabis, CBD doesn’t have psychoactive effects. That means you can use it for medicinal purposes without getting high, so it’s safe to utilize even when you’re planning to work or drive. CBD is also an extremely adaptable compound, so it can be transformed into oils, gummies, pills, creams and more to suit various therapeutic needs.
CBD is the best researched of the cannabinoid compounds, and its applications are exceptionally wide-ranging. Studies show that CBD can be used for:
CBD — Reported Therapeutic Effects
1. Anxiety and stress
5. Withdrawal symptoms in cannabis and tobacco addiction. Inhibition of the reward-facilitating effect of morphine and cocaine.
6. Auto-immune diseases (diabetes type 1 for example)
7. Auto-immune-like diseases (GVHD, for example)
9. Inflammation (Crohn's disease, colitis, pancreatitis, rheumatoid arthritis).
10. Reduces infarct size and increase blood flow in stroke;
11. Obesity (food consumption; lowering appetite); metabolic syndrome.
12. Retinopathy associated with diabetes.
13. Antiemetic and anti-nausea
14. Protects against myocardial, liver, renal ischemic/reperfusion injury
15. Protects against hypoxia/ischemia injury.
16. Neuroprotection against neuronal damage due to neurological diseases or injury (Parkinson's disease; Huntington's disease; Alzheimer's disease; cerebral infarction; hepatic encephalopathy; traumatic brain injury; cerebral ischemia; spinal cord injury; memory rescuing effects; ).
17. Cancer and resistance to cancer chemotherapy; cancer cell migration (metastasis); inhibits angiogenesis.
18. Epilepsy and convulsions.
19. Chronic inflammatory and neuropathic pain
20. Lowers cannabis and THC effects such as memory loss, psychotic-like symptoms, anxiogenic action
21. Protects against airway obstruction
22. Obsessive-compulsive behavior
23. Memory rescuing effects due to neurodegenerative disorders
25. Reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia
26. Restless leg syndrome
27. Disrupts the consolidation of specific and generalized fear memories
28. Preventing the development of chemotherapy-induced peripheral neuropathy
31. Kidney injury
32. Familial Mediterranean fever (auto-immune)
34. Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats
Cannabidiolic acid, generally abbreviated to CBDA, is a cannabinoid produced by the stems, leaves, and flowers of some cannabis plants. Through a process called decarboxylation, the acid is removed from CBDA, transforming it into CBD. This process is most often performed by heating or smoking cannabis varieties that are high in CBDA. For this reason, CBDA is sometimes considered the “precursor” to CBD.
CBD and CBDA share similar molecular structures, so their therapeutic effects are also similar; however, CBDA has been the subject of less extensive scientific study. Scientists have learned that CBDA works primarily as an inhibitor of the COX-2 enzyme within the endocannabinoid system, leading to exploration of its effectiveness as a treatment for inflammation. Recent studies have also tested the efficacy of CBDA for certain types of cancer, and as an anti-emetic.
CBN is the abbreviation for cannabinol, another compound within the cannabinoid family. In fact, CBN was the first cannabinoid isolated by scientists. CBN is produced when THC is heated or exposed to oxygen; it also occurs naturally as the cannabis plant ages. Even though CBN is derived from THC, it doesn’t share the psychoactive properties of THC.
Within the endocannabinoid system, CBN binds to receptors less effectively than many other cannabinoids. However, it has been studied extensively as a helpful compound to improve sleep health. Scientists have discovered that CBN acts as a powerful sedative, with effects comparable to common sleep-inducing pharmaceuticals like diazepam. In studies on mice, CBN has been shown to prolong sleep time; additional studies suggest that this effect is amplified when used in combination with THC.
Along with its implications for sleep health, CBN has been studied as a possible stimulant for bone tissue growth. Research shows that it may activate stem cells that facilitate the production of new bone, making it potentially useful for the healing of fractures. Additional studies have explored the analgesic, antibiotic, anticonvulsant, and anti-inflammatory applications of CBN.
Like the other compounds in this overview, CBG (short for cannabigerol) is a non-psychoactive cannabinoid with a variety of promising medical applications. CBG is actually the precursor to its more famous cousins, CBD and THC. Like CBDA, exposure to light or heat breaks down CBG in the cannabis plant into these better-known compounds.
Most strains of cannabis contain relatively little CBG, often less than 1%. However, that doesn’t mean this cannabinoid is any less promising when it comes to potential applications. CBG interacts with both CB1 and CB2 receptors in the endocannabinoid system; during these interactions, it’s thought to naturally increase dopamine levels, which help to regulate sleep, mood, and appetite. CBG is also thought to obstruct GABA uptake in the brain and block serotonin receptors—both positive implications for the treatment of anxiety and depression.
Studies have found CBG especially effective for certain physiological systems and symptoms, including:
Endocannabinoid receptors are highly concentrated in the structures of the eye, and CBG has been shown particularly effective at reducing the intraocular pressure associated with glaucoma.
A recent study offered promising results for CBG as a cancer-fighting compound, with the potential to block the receptors that cause cancer cell growth. Scientists saw inhibition in the growth of colorectal cancer cells in mice that were treated with CBG, offering an exciting new avenue of treatment for cancer patients.
Discovered more than five decades ago, cannabichromene (abbreviated CBC) is considered one of the most promising cannabinoids in recent medical research. Like CBD and THC, CBC is derived from CBDA when the acid is broken down by exposure to heat or ultraviolet light.
Non-intoxicating like other CBD compounds, CBC is less well researched than some cannabis derivatives. However, scientists have discovered a variety of potential applications for this cannabinoid.
Within the endocannabinoid system, CBC binds most effectively with vanilloid receptor 1 (TRPV1) and transient receptor potential ankyrin 1 (TRPA1); both of these receptor types are linked to the body’s perception of pain. This means that CBC may function as an alternative to traditional painkillers like NSAIDS, but without their potentially harmful side effects. CBC may be particularly effective for treating inflammatory conditions like osteoarthritis, especially when used in combination with THC.
Additional studies have shown that CBC may be a potential cancer fighter, second only to CBG in inhibiting the growth of cancer cells. Though research in this field is limited so far, the anti-inflammatory properties of CBC may also make it an effective acne treatment; studies suggest that it could work to prevent the sebaceous gland inflammation at the root of many types of acne.
While these therapeutic benefits overlap with many other cannabinoids, CBC is differentiated by what’s known as the “entourage effect.” Researchers believe that CBC may work synergistically when used with other cannabinoids to provide even more effective treatments for many of the conditions outlined above.
Last in our roundup of cannabinoid compounds is cannabidivarin, better known as CBDV. CBDV is extremely similar to CBD on a molecular level, but recent research has shown its applications are exceptionally unique and valuable for people with neurological disorders.
Preliminary studies on mice show that CBDV has enormous untapped potential in the treatment of epilepsy and similar neurological conditions. As an anticonvulsant and antiepileptic, CBDV may be able to help patients who suffer from epilepsy, Parkinson’s disease, and other conditions in which seizures may occur. Along with reducing the duration and intensity of seizures, CBDV could work to prevent convulsions in the event that a seizure does occur. Early research on these applications for CBDV is so promising that GW Pharmaceuticals, a cannabis-focused company based in England, is working to patent the use of CBDV for the treatment of seizures.
Along with seizure treatment, CBDV may be used by patients who experience vomiting and nausea, especially when those conditions are caused by chemotherapy. It has also been studied as an appetite suppressant, and as a treatment that relieves symptoms of Crohn’s disease and multiple sclerosis.
Like all of the cannabinoids discussed above, CBDV is non-psychoactive.
Disclaimer: These statements have not been evaluated by the Food and Drug Administration. Products discussed are not intended to diagnose, treat, cure, or prevent any disease.
On the way to legalization in Israel: After a round of discussions with the leaders of the struggle, the PM agreed on a full pardon for cannabis consumers (deletion of criminal cases).
After a round of discussions during which meetings were held between Prime Minister Benjamin Netanyahu and Chairman of the Green Leaf Movement and editor of Cannabis Oren Leibowitz magazine and between Justice Minister Amir Ohana and Attorney Hatz-David Ozer, the PM decided to adopt the main elements of the "Leaf Plan" green.
The plan includes retroactive amnesty and deletion of criminal records of self-use of cannabis for some 40,000 Israelis, and the establishment of a committee to promote the legalization of a legal cannabis market in Israel (legalization), including opening legal stores and permitting domestic growth.
During the meetings, leaders of the legalization movement in Israel presented Leibowitz and helped Netanyahu and her data on the current harms of the anti-cannabis consumer policy and details on Canada's successful legalization model.
The petition details presented by the two on behalf of thousands of supporters (the High Court of Cannabis), including a demand for a complete abolition of the market and regulate the market in a controlled manner (legalization). The first hearing in the future will take place in the High Court in two months (22.4).
Apart from eliminating criminal cases in the context of mass pardon and the establishment of the first legalization committee in Israel, the parties intend to promote immediate solutions to reduce medical cannabis prices in pharmacies - these have jumped to an all-time high as a result of industry reform.
I examined the issue and decided to promote the deletion of criminal record for tens of thousands of Israelis for personal use and possession of cannabis, causing unnecessary suffering to many and burdens in the courts. Minister Ohana began work on the issue and he will chair a committee with professionals and Oren Leibowitz, chairman of Green Leaf, who will examine the import of the model in Canada to regulate a legal market in Israel
A first announcement of the program was posted on Twitter on Twitter and Facebook symbolically at exactly 4:20 this afternoon. More updates are expected later this week. The legalization committee will be formed soon and will be chaired by Minister Ohana Belibowitz.
This decision is a continuation of what Netanyahu said in the April 2019 elections, when he stated that he intended to abolish the inclusion of cannabis consumers. Ahead of the second round of elections in September 2019, Netanyahu has already announced steps to legalize. In the meantime, he said he would support a bill that would allow cannabis plant growth in the home.
Justice Minister Ohana also commented on the issue when he expressed support for full legalization several times. The current decision is another step forward, this time more practical, to the realization of the fight for legalization, should the right bloc reach 61 seats.
Source: Israel Cannabis Magazine
According to the old regulation, the price of medical cannabis in Israel stood at NIS 370 a month - regardless of the amount of cannabis licensed. So how much does medical cannabis cost and how much money is spent on each month?
In 2009, the medical cannabis industry was first established in Israel. Initially, cannabis raised a number of sick people in their homes with the approval of the Ministry of Health, and later also supplied some of the produce to several other patients. As the field grew and developed, the Ministry of Health decided to take action and regulate the industry.
Old set - only NIS 370
With the regulation of the industry, a uniform price was set, which all medical cannabis patients would pay. When the question came up of how much medical cannabis cost, the price was set at a random rate, by the special formula of "Double Live." HI is known as 18 in Gematria. Double 2 is 36 - and from there the price is set at NIS 360 a month. After about a year, the office decided to update the price of medical cannabis and raise it to NIS 370. It doesn't matter if the patient receives 20 grams of cannabis a month, or 200 grams of cannabis a month - the cost, NIS 370, remains the same.
New series - up to NIS 2,000 or more
Following pharmacy reform and the move to a free market format, medical cannabis prices jumped to new highs. Pricing is determined for each product individually, for example, a 10-gram bag costs between NIS 180 and NIS 390 today. Each company competes with its products as it sees fit. Cannabis companies oppose this model, as they say it will hurt them financially.
So how much does medical cannabis cost today?
After implementation of the new regulation, prices jumped to record prices, in the framework of "free market", up to NIS 2,000 and even more. The price is determined by the amount of cannabis the patient receives. , Or a vial of medical cannabis oil. Most companies charge between NIS 180 and 250 for a medical cannabis bag at a pharmacy. Some of the products of other companies come up to NIS 390 per bag.
Full Price List
|BOL Pharma||Oil||BOL T0/C24 CELIXIR24||$52.48||$52.48||$52.48||$52.48|
|BOL Pharma||Flower||BOL T0/C24 Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Flower Shredded||BOL T0/C24 G.Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Oil||BOL T1/C20 CELIXIR20||$52.48||$52.48||$52.48||$52.48|
|BOL Pharma||Flower||BOL T1/C20 Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Flower Shredded||BOL T1/C20 G.Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Oil||BOL T10/C10 EQUATIR10||$52.48||--||$52.48||$52.48|
|BOL Pharma||Flower||BOL T10/C10 Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Flower Shredded||BOL T10/C10 G.Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Flower||BOL T10/C2 Indica Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Flower Shredded||BOL T10/C2 Indica G.Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Flower||BOL T10/C2 Sativa Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Flower Shredded||BOL T10/C2 Sativa G.Flowers||$55.39||$42.57||$55.39||$51.02|
|BOL Pharma||Oil||BOL T10/C2 TELIXIR10||$52.48||$52.48||--||$52.48|
|BOL Pharma||Oil||BOL T10/C2 TELIXIR10 Indica||$52.48||$52.48||$52.48||$52.48|
|BOL Pharma||Oil||BOL T10/C2 TELIXIR10 Sativa||$52.48||$52.48||$52.48||$52.48|
|BOL Pharma||Flower||BOL T15/C3 Indica Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Flower Shredded||BOL T15/C3 Indica G.Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Flower||BOL T15/C3 Sativa Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Flower Shredded||BOL T15/C3 Sativa G.Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Oil||BOL T15/C3 TELIXIR15||$52.48||$52.48||$52.48||$52.48|
|BOL Pharma||Flower||BOL T20/C4 Indica Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Flower Shredded||BOL T20/C4 Indica G.Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Flower||BOL T20/C4 Sativa Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Flower Shredded||BOL T20/C4 Sativa G.Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Oil||BOL T20/C4 TELIXIR20||$52.48||$52.48||$52.48||$52.48|
|BOL Pharma||Oil||BOL T3/C15 CELIXIR15||$52.48||$52.48||--||$52.48|
|BOL Pharma||Flower||BOL T3/C15 Flowers||$55.39||$42.57||$55.39||$51.02|
|BOL Pharma||Flower Shredded||BOL T3/C15 G.Flowers||$55.39||$55.39||--||$55.39|
|BOL Pharma||Oil||BOL T5/C10 CELIXIR10||$52.48||$52.48||--||$52.48|
|BOL Pharma||Flower||BOL T5/C10 Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Flower Shredded||BOL T5/C10 G.Flowers||$55.39||$55.39||$55.39||$55.39|
|BOL Pharma||Oil||BOL T5/C5 EQUATIR5||$52.48||$52.48||--||$52.48|
|BOL Pharma||Flower||BOL T5/C5 Flowers||$55.39||--||$55.39||$55.39|
|BOL Pharma||Flower Shredded||BOL T5/C5 G.Flowers||$55.39||--||--||$55.39|
|BOL Pharma||Oil||CONNEXIR T1/C20||$52.48||--||--||$52.48|
|IMC||Flower||IMC Flow T10C10 PARIS||$63.85||--||--||--|
|IMC||Flower||IMC Flow T15C3ind LONDON||$63.85||--||--||--|
|IMC||Flower||IMC Flow T15C3sat DQ||$63.85||--||--||--|
|IMC||Flower||IMC Flow T20C4ind ROMA||$78.43||--||--||--|
|IMC||Flower||IMC Flow T20C4sat TLV||$63.85||--||--||--|
|IMC||Oil||IMC Oil T15C3 CAN||$63.85||--||--||--|
|Syqe Medical||Evaporation Cartridge||Syqe Inhaler cartridge 60||$215.74||--||--||$215.74|
|Bazelet||Flower Shredded||BAZELET T1/C20||$56.85||--||--||$56.85|
|Bazelet||Flower Shredded||BAZELET T10/C10||$56.85||--||--||$56.85|
|Bazelet||Flower Shredded||BAZELET T10/C2||$56.85||--||--||$56.85|
|Bazelet||Flower Shredded||BAZELET T15/C3||$56.85||--||--||$56.85|
|Bazelet||Flower Shredded||BAZELET T3/C15||$56.85||--||--||$56.85|
|Bazelet||Flower Shredded||BAZELET T5/C10||$56.85||--||--||$56.85|
|Bazelet||Flower Shredded||BAZELET T5/C5||$56.85||--||--||$56.85|
|Better||Flower||BETTER INFLOR T10/C10 IMM||$75.80|
|Better||Flower||BETTER INFLOR T10/C2 SATI||$46.65|
|Better||Flower||BETTER INFLOR T15/C3 ABLE||$75.80|
|Better||Flower||BETTER INFLOR T15/C3 ACTI||$104.96|
|Better||Flower||BETTER INFLOR T15/C3 BALA||$75.80|
|Better||Flower||BETTER INFLOR T15/C3 COMF||$75.80|
|Better||Flower||BETTER INFLOR T15/C3 IND||$104.96|
|Better||Flower||BETTER INFLOR T20/C4 RELI||$104.96|
|Better||Flower||BETTER INFLOR T20/C4 STEA||$84.55|
|Better||Flower||BETTER INFLOR T20/C4 SUPP||$113.70|
|Better||Flower||BETTER INFLOR T3/C15 CURE||$75.80|
|Better||Flower||BETTER INFLOR T5/C10 EFFE||$75.80|
|Better||Oil||BETTER OIL T1/C20 CURE||$75.80|
|Better||Oil||BETTER OIL T1/C20 EFFECTI||$75.80|
|Better||Oil||BETTER OIL T10/C10 IMMUNE||$75.80|
|Better||Oil||BETTER OIL T10/C2 BUILD||$46.65|
|Better||Oil||BETTER OIL T15/C3 COMFORT||$46.65|
|Better||Oil||BETTER OIL T20/C4 SUPPORT||$84.55|
|Teva Adir||Flower||TEVADIR DQ T15/C3 SAT.FLO||$72.89||$72.89|
|Teva Adir||Flower||TEVADIR FEDE T15/C3 SAT F||$72.89|
|Teva Adir||Flower||TEVADIR JUAN T5/C10 FLOWE||$72.89|
|Teva Adir||Flower||TEVADIR ML T15/C3 IND.FLO||$72.89||$72.89|
|Teva Adir||Flower||TEVADIR MOR C15/T3 FLOWER||$78.72|
|Teva Adir||Oil||TEVADIR MOR T3/C15 OIL||$72.89|
|Teva Adir||Flower||TEVADIR RM T10/C10 FLOWER||$78.72|
|Teva Adir||Oil||TEVADIR T10/C10 OIL||$78.72|
|Teva Adir||Oil||TEVADIR T10/C2 OIL||$72.89|
|Teva Adir||Oil||TEVADIR T15/C3 OIL||$72.89|
|CannDoc||Flower||T1/C20 CBD CANNDOC||$56.85|
|CannDoc||Flower||T10/C2 INDICA CANNDOC||$52.48|
|CannDoc||Flower||T10/C2 SATIVA CANNDOC||$52.48|
|CannDoc||Flower||T15/C3 INDICA CANNDOC||$56.85|
|CannDoc||Flower||T15/C3 SATIVA CANNDOC||$56.85|
|CannDoc||Flower||T20/C4 INDICA CANNDOC||$58.31|
|CannDoc||Flower||T20/C4 SATIVA CANNDOC||$58.31|
|CannDoc||Flower||T3/C15 CBD CANNDOC||$49.56|
|CannDoc||Flower||T5/C10 CBD CANNDOC||$49.56|
|CannDoc||Flower||T5/C5 CANNDOC INFLOR||$54.23|
|CannDoc||Oil||T5/C5 CANNDOC OIL||$55.39|
|Rafa||Oil||AXIBAN SL DROPS T1/C20||$76.97||$78.72||$76.97||$77.55|
|Rafa||Oil||AXIBAN SL DROPS T10/C10||$55.10||$58.31||$55.10||$56.27|
|Rafa||Oil||AXIBAN SL DROPS T10/C2||$44.02||$46.65||$44.02||$44.90|
|Rafa||Oil||AXIBAN SL DROPS T15/C3||$65.89||$67.06||$65.89||$66.18|
|Rafa||Oil||AXIBAN SL DROPS T3/C15||$65.89||$67.06||$65.89||$66.18|
|Rafa||Oil||AXIBAN SL DROPS T5/C10||$55.10||$58.31||$55.10||$56.27|
|Rafa||Oil||AXIBAN SL DROPS T5/C5||$50.44||$51.02||--||$50.73|
|Seach||Flower||Canary Indica T10/C2||$52.48||$52.48||--||$52.48|
|Seach||Flower||Canary Indica T15/C3||$53.94||$46.65||--||$50.44|
|Seach||Flower||Canary Indica T20/C4||$53.94||$46.65||--||$50.44|
|Seach||Flower||Canary Sativa T10/C2||$52.48||$49.56||--||$51.02|
|Seach||Flower||Canary Sativa T15/C3||$53.94||$52.48||--||$53.35|
|Seach||Flower||Canary Sativa T20/C4||$53.94||$46.65||--||$50.44|
|Seach||Flower||Nitzan T10/C2 Indica||$60.93||$60.93||--||$60.93|
|Seach||Flower||Nitzan T10/C2 Sativa||$60.93||$60.93||--||$60.93|
|Seach||Flower||Nitzan T15/C3 Indica||$68.22||$68.22||--||$68.22|
|Seach||Flower||Nitzan T15/C3 Sativa||$68.22||$68.22||--||$68.22|
|Seach||Flower||Nitzan T20/C4 Indica||$72.59||$72.59||--||$72.59|
|Seach||Flower||Nitzan T20/C4 Sativa||$72.59||$72.59||--||$72.59|
Next week in pharmacies: "Bazelet" company with first import of overseas cannabis from the T20 category. "Ensure continuous supply of high-quality, clean cannabis," says the company's CEO. Accurate THC percentages will be displayed for the first time.
Bazelet first imported about half a ton of cannabis from Portugal last week to fill the shortage of high-quality cannabis pharmacies from the T20 category. Early next week, the new products should be available in patient pharmacies.
Bazelet's imported cannabis comes from EU-GMP standard incubators and is the first in Israel to show an accurate percentage of THC and not just the category (T20 in this case), so patients can know better what they are getting - in this case between 19.3% and 20.8% THC.
Although the Ministry of Health has promised that there will be an obligation to present an accurate quantity of active ingredients as of 1.1.20, the rest of the manufacturers are still not properly marking and the products may contain between 16% and 24% of THC in the case of T20 and a similar gap in other categories.
Cannabis, weighing 400 kilograms, was shipped to Israel by the recently acquired cannabis Portuguese company Terra Verde, acquired by the European cannabis company EMMAC (EMMAC).
Cannabis will be marketed in Israel under the Bazelet home brand, "BCANN" (BCANN), underneath which cannabis products purchased from independent growing companies in Israel and worldwide. At the same time, “Bazelet” manufactures branded products for other companies.
The new cannabis imported by the “Bazelet” company from Portugal Packed in the company plants The BCANN cannabis flower T20 / C4 of the BCANN series of Bazelet cannabis flower T20 of the BCANN series from Portugal
Meir Ariel, CEO of the Bazelet Group, said: "As a leading player in the medical cannabis industry in Israel, the Bazelet Group does everything it can to ensure a continuous supply of premium, high-quality and clean medical cannabis."
Ariel also addressed the issue of export, saying: “Israeli patients are our top priority and we will take care of the first. We will not export cannabis abroad until we resolve their plight and ensure the continuity of their treatment. ”
One of the reasons for C20's cannabis shortage, the one imported by Bazelet, is that in the past, companies released unreliable data and now, after being determined to comply with the standards, find that the same products contained less than declared - the Ministry of Health explains.
The shipment that Bazelet brought is the second to arrive in Israel from Portugal after a few years before it did so, "CannDoc", which imported 250 kg from the facilities of "Tlray". There, too late, hope to transfer Portuguese cannabis to the pharmacies soon.
Thus, a total of 650 kg of medical cannabis has been imported to Israel so far - all from Portugal, which is the largest medical cannabis exporter in Europe. Most Canadian companies, as well as Israeli companies, set up facilities in Portugal to export cannabis throughout Europe.
Source: Cannabis Magazine Israel
Comprehensive marijuana reform will be at the center of another congressional hearing next week, a key committee announced on Wednesday.
Two months after the House Judiciary Committee approved the Marijuana Opportunity, Reinvestment and Expungement (MORE) Act, a comprehensive cannabis legalization bill sponsored by Chairman Jerrold Nadler (D-NY), the issue will be the subject of another discussion in an Energy and Commerce Subcommittee.
The topic will be taken up by the panel’s Subcommittee on Health on January 15.
“As public opinion continues to evolve and cannabis policies change at all levels of government, it’s important to bring federal agency officials together to discuss current and future federal cannabis policies,” Energy and Commerce Chairman Frank Pallone (D-NJ) and Health Subcommittee Chairwoman Anna Eshoo (D-CA) said in a joint statement. “We’re particularly interested in examining the implications of changing marijuana’s schedule listing, the potential of cannabis research, and federal efforts to review and approve cannabidiol products.”
NEWS: Health Subcommittee announces a legislative hearing on current and future federal cannabis policies.
It’s not clear if the hearing, titled the “Cannabis Policies for the New Decade,” will focus on specific legislation such as the MORE Act. So far, the committee has not listed any witnesses who will testify at the meeting.
“The Energy and Commerce committee taking up marijuana reform is an unprecedented and welcome development,” Justin Strekal, political director of NORML, told Marijuana Moment. “As the MORE Act continues to move through the process, the House is poised to become the first chamber of Congress in history to pass a bill to end prohibition.”
Nadler previously told Marijuana Moment that his office was “carrying on conversations” with other committees that his bill had been referred to, such as Energy and Commerce, to see if they’d waive jurisdiction in order to advance it more quickly to the full floor.
“I don’t anticipate that to be a big problem,” he said. “We are looking forward to moving this to the floor at an appropriate time when we’ve done some more educational work and have the votes.”
The Small Business Committee said this week that it’s agreed to yield on the bill.
Marijuana Moment has reached out to staffers on each of the panels, but while several responded, they said plans haven’t been finalized yet. A National Resources Committee communications official said he “wouldn’t put us down as a potential obstacle” on the legislation’s path to the floor.
The legislation has also been referred to Agriculture, Education and Labor, Ways and Means, and Oversight and Reform.
Nadler’s MORE Act has been a subject of intense interest for cannabis reform advocates, who view it as an ideal vehicle to end federal prohibition and repair the harms of the drug war, particularly for communities of color.
Beside descheduling marijuana, the bill would expunge the records of those with prior cannabis convictions and impose a five percent tax on sales, revenue from which would be reinvested in those disproportionately impacted communities.
It would also create a pathway for resentencing for those incarcerated over marijuana offenses, and it would provide protections ensuring that immigrants couldn’t be denied citizenship over cannabis. Additionally, the legislation would prevent federal agencies from denying public benefits or security clearance due to marijuana use.
It’s not clear if and when Energy and Commerce plans to hold a possible markup to vote on the legislation following Wednesday’s subcommittee hearing but, given the number of other panels that could also choose to take it up and the pressure from advocates to advance the legislation this Congress, it seems likely that such action will be scheduled in a timely fashion.
Source: Marijuana Moment
Thailand's first cannabis clinic opened on Monday (Jan 6) and was flooded with patients after the country became the first in Asia to legalise medicinal use of the drug.
Hundreds of patients converged on the government run facility in Bangkok - which already has a waiting list of more than 2,000.
The pilot clinic, based in the Ministry of Public Health, expects to see between 200 to 300 patients daily.
Public Health Minister Anutin Charnvirankul said today that patients would receive free treatment for the first two weeks. He said: ''This is a pilot clinic, because we cannot produce enough doctors with expertise in cannabis.''
The Southeast Asian country legalised marijuana for medical use and research in 2017. While in 2019 it removed cannabis and hemp extracts from its banned drugs list and pushed laws allowing each household to grow up to six plants.
In a protectionist move to boost the country's economy, only domestic drugs firms and farmers will be able to supply the country's network of clinics.
Health Minister Anutin Charnvirankul said there were already around two dozen smaller non-specialist cannabis centres that form part of general hospitals that see patients sporadically.
But the clinic he opened today (Jan 6) is the first one that will be the first full-time facility staffed by doctors who are experts in medicinal marijuana, he said.
Thailand plans to open 77 similar clinics in the future - one in each of its provinces.
Israeli researchers have developed a medical protocol detailing how cannabis in the elderly should be best treated, and also examined in a preliminary study. The results are impressive - 85% reported an improvement in their health, and researchers recommend that doctors consider the treatment of elderly cannabis as an alternative to narcotic drugs.
Cannabis treatment is effective for elderly people with chronic pain, sleep deprivation, loss of appetite, nausea, and post-traumatic stress disorder (PTSD), helping to reduce their use of narcotic drugs In the elderly with cannabis in the best way.
Researchers at Ben Gurion University, Soroka Hospital's Cannabis Clinical Research Institute, and Niamedic Clinic conducted a study designed to test the efficacy of the medical protocol they developed, which involved 184 elderly patients treated with cannabis according to the protocol and monitored for six months.
The results of the study, together with the therapeutic protocol itself, were published last month in the Journal of Clinical Medicine, entitled "Medical Cannabis for Older Patients - Protocol of Treatment and Preliminary Results". The research was carried out by Dr. Ran Abuchatzira, Dr. Adi Ron and Inbal Sikorin.
Medical Cannabis for the Elderly - Treatment Protocol
"Because there are no established protocols with proven efficacy in treating elderly people with medical cannabis, we have developed one of ours that emphasizes close examination of the effects and side effects, and a slow and gradual start of THC oil, CBD oil, or a combination of the two [and not smoking]," says D. ”Dr. Abuhtsira of the Faculty of Medical Sciences at Ben-Gurion University.
According to the protocol, there are two cornerstones on which the treatment of cannabis in the elderly should be based: starting the lowest dose and gradual increase, and frequent monitoring and review. The goal is to reduce the side effects of treatment as much as possible, with the key phrase for researchers being 'non-harmony primacy' ('first, do no harm') - a fundamental principle of medical ethics.
The first steps, therefore, are designed to ensure that cannabis treatment is indeed appropriate for the patient. The appropriate contraindications for treating elderly cannabis by protocol are chronic pain, Parkinson's disease, sleep disorders, post-traumatic anorexia, convulsions, and palliation (alleviating the suffering of terminally ill patients). Severe cardiovascular disease, risk factors for psychosis, history of addictions, and problems with posture are the contraindications that the physician should consider as reasons to avoid cannabis treatment.
The treatment protocol also places special emphasis on the issue of polypharmacy (multi-drug) in the elderly, with the end goal being that successful cannabis treatment will allow the geriatric patient to reduce the doses of the other drugs he is taking, and even stop taking them. This is actually the last step in the treatment protocol, as seen in the diagram:
“If the treatment is effective and the side effects are not severe, a change in the concomitant treatment with other drugs, especially discontinuation or dosing of opioids, benzodiazepines, and psychotropic and other analgesics, can be considered. Our experience shows that cannabis has the potential to reduce the use of these drugs, ”said Dr. Abuhtsira.
The protocol also addresses concerns that may arise in older patients about the use of cannabis: "The stigma associated with the use of 'cannabis' may prevent patients from agreeing to medical cannabis treatment - even though it is a relatively safe and effective drug," it said. “It is therefore very important to explain to the patient and his / her family the potential benefits and dangers before starting cannabis treatment. This explanation should be given by a nurse or doctor who is proficient in cannabis treatment. ”
Cannabis dose I started to treat the elderly: 5 mg / day
The next step is to determine the cannabinoid ratio and the appropriate dose for the patient. The recommended method of consumption, according to the protocol, is always a sub-lingual drizzle of cannabis oil. For most labels, researchers recommend oil with an equal ratio of THC to CBD ('balanced'), or a combination of dominant THC oil with dominant CBD oil, so that an equal dose of both is obtained.
For the labels of chronic pain from neuropathic origin, sleep disorders and post-traumatic stress, it is recommended to treat only CBD-containing oil with as little as THC.
The recommended starting dose is 5 mg of THC and CBD (or only CBD, depending on the schedule) per day, divided into three daily doses - 1.7 mg per dose. This is exactly the dose that contains every drop of cannabis oil with a concentration of 5% THC and 5% CBD, so it is the ideal concentration for starting treatment.
The dose should be increased by 5 mg every 3 days, until an effective dose is reached. In case of side effects, you should reduce back to the previous dose for another 3 days, then try raising again.
The maximum daily dose recommended in the protocol is up to 40 mg THC per day. For those who are treated with CBD alone, they do not have a maximum dose of 40 mg, but CBD therapy is recommended to start with the same dose and gradually in combination with THC and CBD.
Elderly care for cannabis: 85% satisfied
184 patients with an average age of 81.2 participated in the study through a customized geriatric clinic. After 6 months of cannabis use 58.1% of them chose to continue cannabis treatment and the rest discontinued for such and other reasons, which probably shows that treatment is not suitable for everyone.
Of those who continued treatment, 84.8% reported that there was a moderate or significant improvement in their health status from the start of treatment, and 44% reported that there was a significant improvement in their health status since the start of treatment.
33.6% of patients reported any side effects, with the most common being dizziness (12.1% of patients) and fatigue / fatigue (11.2% of patients). It is important to remember that this is an adult population that is sensitive to side effects, and according to the researchers "the rate of side effects, especially the serious side effects, was relatively low".